Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
第一作者:
Haixia,Fu
第一单位:
Peking University People's Hospital, Peking University Institute of Haematology, No. 11 Xizhimen South Street, Beijing, 100044, China.;Collaborative Innovation Center of Haematology, Peking University, Beijing, China.;Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.;National Clinical Research Center for Haematologic Disease, Beijing, China.
作者:
主题词
人类(Humans);移植物抗宿主病(Graft vs Host Disease);造血干细胞移植(Hematopoietic Stem Cell Transplantation);甾类(Steroids);间质干细胞(Mesenchymal Stem Cells);转化生长因子β(Transforming Growth Factor beta);急性病(Acute Disease);间质干细胞移植(Mesenchymal Stem Cell Transplantation)
DOI
10.1186/s12916-024-03275-5
PMID
38413930
发布时间
2024-11-15
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文